Immunovia
In Brief This Week: Abbott, Thermo Fisher Scientific, Danaher, Oncocyte, Biocartis, More
News items for the week of Feb. 20, 2023.
Immunovia Reducing Headcount, Realigning to Focus on Pancreatic Cancer Test Commercialization
The firm said it will reduce in-house R&D staff from its operations in Lund, Sweden, as it focuses on bringing the ImmRay PanCan-d test to the US market.
Earnings Roundup: Sera Prognostics, Aspira Women's Health, Immunovia, More
Sera, Aspira, Immunovia, Prenetics, ProPhase Labs, and Devyser reported quarterly financial results this week.
Immunovia Gets California Lab License for Pancreatic Cancer Test
The new license will allow Californian physicians to order Immunovia's Immray PanCan-d test for patients.
Immunovia Cleared to Offer Pancreatic Cancer Test in Rhode Island
The test is designed to detect nine serum biomarkers of pancreatic ductal adenocarcinoma, including the protein CA19-9.
Feb 17, 2022
Immunovia Revenues More Than Double in Q4, FY 2021
Jun 4, 2020
Immunovia Raises $43M Through Stock Issuance
Sep 27, 2018
Jun 8, 2018